Abstract
Simple SummaryStandardization of flow-cytometric assessment of minimal residual disease in acute lymphoid leukemia (ALL) is necessary to allow concordant multicentric application of the methodology. This is a prerequisite for internationally collaborative trials, such as the AIEOP-BFM-ALL and the ALL IC-BFM trial. We developed and applied a comprehensive training and quality control program involving a large number of international laboratories within the I-BFM consortium to complement standardization of the methodology with an educational component as well as with persistent quality control measures to allow large ALL treatment trials which use multi-laboratory FCM-MRD assessments for risk stratification of pediatric patients with ALL.Monitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD in large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels of expertise and their performance quality should be continuously monitored. We sought to install a unique and comprehensive training and quality control (QC) program involving a large number of reference laboratories within the international Berlin-Frankfurt-Münster (I-BFM) consortium, in order to complement the standardization of the methodology with an educational component and persistent quality control measures. Our QC and quality assurance (QA) program is based on four major cornerstones: (i) a twinning maturation program, (ii) obligatory participation in external QA programs (spiked sample send around, United Kingdom National External Quality Assessment Service (UK NEQAS)), (iii) regular participation in list-mode-data (LMD) file ring trials (FCM data file send arounds), and (iv) surveys of independent data derived from trial results. We demonstrate that the training of laboratories using experienced twinning partners, along with continuous educational feedback significantly improves the performance of laboratories in detecting and quantifying MRD in pediatric ALL patients. Overall, our extensive education and quality control program improved inter-laboratory concordance rates of FCM-MRD assessments and ultimately led to a very high conformity of risk estimates in independent patient cohorts.
Highlights
The application of flow cytometric minimal residual disease measurement (FCMMRD) has become a routine clinical practice in most current study protocols worldwide, in order to assign patients to different risk groups and to tailor treatment intensity [1,2,3,4,5,6].flow cytometry (FCM)-MRD is applicable in almost all (>98%) patients with lymphoblastic leukemia and can reach sensitivities similar to a quantitative real-time polymerase chain reaction (RQ-PCR)(≥10−5 ) if it is ensured that the laboratories involved in MRD testing are able to reliably detect and quantify leukemic cells, even in the low MRD range [1]
As of November 2020, twenty-two trainee and seven expert trainer laboratories participated in a twinning maturation program and all trainee laboratories achieved maturation status, enabling them to report FCM-MRD results for clinical decision making without further control by partner laboratories according to the study group’s guidelines
Forty-one international Berlin-Frankfurt-Münster (I-BFM)-FLOW laboratories submitted results in the most recent LMD file send around (RT2020) and data on 1679 results of 29 issued external quality assurance (QA) ring trials (UK NEQAS) of up to 38 laboratories participating per ring trial were collected
Summary
The application of flow cytometric minimal residual disease measurement (FCMMRD) has become a routine clinical practice in most current study protocols worldwide, in order to assign patients to different risk groups and to tailor treatment intensity [1,2,3,4,5,6].FCM-MRD is applicable in almost all (>98%) patients with lymphoblastic leukemia and can reach sensitivities similar to a quantitative real-time polymerase chain reaction (RQ-PCR)(≥10−5 ) if it is ensured that the laboratories involved in MRD testing are able to reliably detect and quantify leukemic cells, even in the low MRD range [1]. Several national centers and international consortia previously worked on standardizing the FCM-MRD methodology in multi-centric settings to improve inter-laboratory concordance rates, and to assure sensitive and accurate MRD assessments [5,7,8,9,10,11]. This study, involving four experienced national reference laboratories, proved that FCM-MRD can be standardized for multi-centric application in large trials. Such a multi-facetted QC/quality assurance (QA) program included the standardization of the methodology, continuous staff training, performance reviews through sample and list-mode data (LMD) exchange, as well as the assessment of concordance of “on trial”
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
